On June 24, 2025, Titan Pharmaceuticals, Inc. entered into a deal to issue 60,000 shares of Series C Convertible Preferred Stock at $10.00 per share, raising a total of $600,000. This security allows the investor to convert shares into common stock at a rate of $3.40 per share.